Cooley advised Oyster Point Pharma on the deal, while Cravath represented Viatris. Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, announced its definitive agreement to be acquired...
You must be a Standard 1 Year member to access this content.
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
You must be a Standard 1 Year member to access this content.
O’Melveny & Myers LLP advised Synaptics Incorporated on the deal. Synaptics amended and restated a credit agreement with the company’s bank lenders, extending the maturity date of its...
You must be a Standard 1 Year member to access this content.
O’Melveny & Myers LLP advised Synaptics Incorporated on the deal. Synaptics announced the sale of US$400 million of senior unsecured notes. The 4% notes, due to mature...
You must be a Standard 1 Year member to access this content.
